Intra-Cluster Correlation Estimates for HIV-related Outcomes from Care and Treatment Clinics in Dar es Salaam, Tanzania

Dale Barnhart, Ellen Hertzmark, Enju Liu, Ester Mungure, Aisa N Muya, David Sando, Guerino Chalamilla, Nzovu Ulenga, Till Bärnighausen, Wafaie Fawzi, Donna Spiegelman, Dale Barnhart, Ellen Hertzmark, Enju Liu, Ester Mungure, Aisa N Muya, David Sando, Guerino Chalamilla, Nzovu Ulenga, Till Bärnighausen, Wafaie Fawzi, Donna Spiegelman

Abstract

Introduction: Researchers planning cluster-randomized controlled trials (cRCTs) require estimates of the intra-cluster correlation coefficient (ICC) from previous studies for sample size calculations. This paper fills a persistent gap in the literature by providing estimates of ICCs for many key HIV-related clinical outcomes.

Methods: Data from HIV-positive patients from 47 HIV care and treatment clinics in Dar es Salaam, Tanzania were used to calculate ICCs by site of enrollment or site of ART initiation for various clinical outcomes using cross-sectional and longitudinal data. ICCs were estimated using linear mixed models where either clinic of enrollment or clinic of ART initiation served as the random effect.

Results: ICCs ranged from 0 to 0.0706 (95% CI: 0.0447, 0.1098). For most outcomes, the ICCs were large enough to meaningfully affect sample size calculations. For binary outcomes, the ICCs for event prevalence at baseline tended to be larger than the ICCs for later cumulative incidences. For continuous outcomes, the ICCs for baseline values tended to be larger than the ICCs for the change in values from baseline.

Conclusion: The ICCs for HIV-related outcomes cannot be ignored when calculating sample sizes for future cluster-randomized trials. The differences between ICCs calculated from baseline data alone and ICCs calculated using longitudinal data demonstrate the importance of selecting an ICC that reflects a study's intended design and duration for sample size calculations. While not generalizable to all contexts, these estimates provide guidance for future researchers seeking to design adequately powered cRCTs in Sub-Saharan African HIV treatment and care clinics.

Keywords: Cluster Randomized Controlled; HIV Infections; Intra-cluster Correlation Coefficient; Multicenter Studies; Sample Size.

Conflict of interest statement

No competing interests were declared by any authors.

References

    1. Global Report . World Health Organization; Geneva, Switzerland: 2013. UNAIDS Report on the Global AIDS Epidemic 2013.
    1. Corbett E.L., Makamure B., Cheung Y.B., Dauya E., Matambo R., Bandason T. HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS. 2007;21(4):483–489.
    1. Boily M.C., Masse B., Alsallaq R., Padian N.S., Eaton J.W., Vesga J.F. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med. 2012;9(7):e1001250.
    1. Cori A., Ayles H., Beyers N., Schaap A., Floyd S., Sabapathy K. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511.
    1. Selke H.M., Kimaiyo S., Sidle J.E., Vedanthan R., Tierney W.M., Shen C. Task-shifting of antiretroviral delivery from health care workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya. J. Acquir. Immune Defic. Syndr. 2010;55(4):483–490.
    1. Chang L.W., Kagaayi J., Nakigozi G., Ssempijja V., Packer A.H., Serwadda D. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One. 2010;5(6):e10923.
    1. Ayles H.M., Sismanidis C., Beyers N., Hayes R.J., Godfrey-Faussett P.Z.A.M.S.T.A.R. The Zambia South Africa TB and HIV reduction study: design of a 2 x 2 factorial community randomized trial. Trials. 2008;9(1):63.
    1. Pagel C., Prost A., Lewycka S., Das S., Colbourn T., Mahapatra R. Intracluster correlation coefficients and coefficients of variation for perinatal outcomes from five cluster-randomised controlled trials in low and middle-income countries: results and methodological implications. Trials. 2011;12:151.
    1. Donner A., Klar N. Pitfalls of and controversies in cluster randomization trials. Am. J. Public Health. 2004;94(3):416–422.
    1. Hayes R.J., Moulton L.H. CRC Press; Boca Raton: 2009. Cluster Randomised Trials.
    1. Murray D.M. Oxford University Press; New York: 1998. Design and Analysis of Group-randomized Trials.
    1. Donner A., Klar N. Cluster randomization trials in epidemiology: theory and application. J. Stat. Plan. Inference. 1994;42(1–2):37–56.
    1. Cornfield J. Randomization by group: a formal analysis. Am. J. Epidemiol. 1978;108(2):100–102.
    1. Murray D.M., Blitstein J.L. Methods to reduce the impact of intraclass correlation in group-randomized trials. Eval. Rev. 2003;27(1):79–103.
    1. Campbell M.K., Piaggio G., Elbourne D.R., Altman D.G., Group C. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.
    1. Ivers N.M., Taljaard M., Dixon S., Bennett C., McRae A., Taleban J. Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8. BMJ. 2011;343:d5886.
    1. Pals S.L., Wiegand R.E., Murray D.M. Ignoring the group in group-level HIV/AIDS intervention trials: a review of reported design and analytic methods. AIDS. 2011;25(7):989–996.
    1. Pals S.L., Beaty B.L., Posner S.F., Bull S.S. Estimates of intraclass correlation for variables related to behavioral HIV/STD prevention in a predominantly African American and hispanic sample of young women. Health Educ. Behav. 2009;36(1):182–194.
    1. Glassman J.R., Potter S.C., Baumler E.R., Coyle K.K. Estimates of intraclass correlation coefficients from longitudinal group-randomized trials of adolescent HIV/STI/pregnancy prevention programs. Health Educ. Behav. 2015;42(4):545–553.
    1. Zhang J., Pals S.L., Medley A., Nichols C., Bachanas P., van Zyl D. Parameters for sample size estimation from a group-randomized HIV prevention trial in HIV clinics in sub-Saharan Africa. AIDS Behav. 2014;18(12):2359–2365.
    1. Li N., Spiegelman D., Drain P., Mwiru R.S., Mugusi F., Chalamilla G. Predictors of weight loss after HAART initiation among HIV-infected adults in Tanzania. AIDS. 2012;26(5):577–585.
    1. Hawkins C., Chalamilla G., Okuma J., Spiegelman D., Hertzmark E., Aris E. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS. 2011;25(9):1189–1197.
    1. Hawkins C., Christian B., Ye J., Nagu T., Aris E., Chalamilla G. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS. 2013;27(6):919–927.
    1. Li N., Manji K.P., Spiegelman D., Muya A., Mwiru R.S., Liu E. Incident tuberculosis and risk factors among HIV-infected children in Tanzania. AIDS. 2013;27(8):1273–1281.
    1. Liu E., Armstrong C., Spiegelman D., Chalamilla G., Njelekela M., Hawkins C. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. Clin. Infect. Dis. 2013;56(12):1820–1828.
    1. Makubi A., Okuma J., Spiegelman D., Hawkins C., Darling A.M., Jackson E. Burden and determinants of severe anemia among HIV-infected adults: results from a large urban HIV program in Tanzania, east Africa. J. Int. Assoc. Provid. AIDS Care. 2015;14(2):148–155.
    1. Muya A.N., Geldsetzer P., Hertzmark E., Ezeamama A.E., Kawawa H., Hawkins C. Predictors of nonadherence to antiretroviral therapy among HIV-infected adults in Dar es Salaam, Tanzania. J. Int. Assoc. Provid. AIDS Care. 2015;14(2):163–171.
    1. Semu H., Zack R.M., Liu E., Hertzmark E., Spiegelman D., Sztam K. Prevalence and risk factors for overweight and obesity among HIV-infected adults in Dar es Salaam, Tanzania. J. Int. Assoc. Provid. AIDS Care. 2014 2325957414542574.
    1. National guideline for the management of HIV and AIDS . third ed. The United Republic of Tanzania MoHaSW; 2008. National AIDS Control Programme (NACP)
    1. Antiretroviral Therapy for HIV Infection in Adults and Adolescents . World Health Organization; 2010. Recommendations for a Public Health Approach.
    1. Eveleth P.B. Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. Am. J. Hum. Biol. 1996;8(6):786–787.
    1. El-Khatib Z., Katzenstein D., Marrone G., Laher F., Mohapi L., Petzold M. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518.
    1. Hankinson S.E., Manson J.E., Spiegelman D., Willett W.C., Longcope C., Speizer F.E. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol. Biomark. Prev. 1995;4(6):649–654.
    1. Hertzmark E., Spiegelman D. Channing Laboratory, Harvard University; Cambridge, MA: 2010. The SAS ICC9 Macro. Available at.
    1. Gulliford M.C., Adams G., Ukoumunne O.C., Latinovic R., Chinn S., Campbell M.J. Intraclass correlation coefficient and outcome prevalence are associated in clustered binary data. J. Clin. Epidemiol. 2005;58(3):246–251.
    1. Rosner B. Cengage Learning; 2010. Fundamentals of Biostatistics; pp. 381–389.
    1. Kerry S.M., Bland J.M. Statistics notes: the intracluster correlation coefficient in cluster randomisation. BMJ. 1998;316(7142):1455–1460.
    1. Ionan A.C., Polley M.Y., McShane L.M., Dobbin K.K. Comparison of confidence interval methods for an intra-class correlation coefficient (ICC) BMC Med. Res. Methodol. 2014;14:121.
    1. Hayes R.J., Bennett S. Simple sample size calculation for cluster-randomized trials. Int. J. Epidemiol. 1999;28(2):319–326.
    1. Thomson A., Hayes R., Cousens S. Measures of between-cluster variability in cluster randomized trials with binary outcomes. Stat. Med. 2009;28(12):1739–1751.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir